

Marked-up Claim:

9. (Amended) The compound or salt of Claim 61 wherein R^6 is $-\text{COR}^{10}$ wherein R_{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein:

R_{11} is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R^{12} is $-\text{NR}^{13}\text{R}^{14}$ wherein R_{13} and R_{14} combine to form a group selected from $-(\text{CH}_2)_4-$, $-(\text{CH}_2)_5-$, $-(\text{CH}_2)_2\text{-O-}(\text{CH}_2)_2-$ **[or]and** $-(\text{CH}_2)_2\text{N}(\text{CH}_3)(\text{CH}_2)_2-$.

12. (Amended) The compound or salt of Claim 61 wherein R_6 is 3-pyrrolidin-1-ylpropylaminocarbonyl, 3-morpholin-4-ylpropylamino-carbonyl, 2-pyrrolidin-1-ylethylamino-carbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-dimethylpiperazin-1-yl)ethyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.

15. (Amended) The compound or salt of Claim 61 wherein R_6 is $-\text{COR}_{10}$ wherein R_{10} is $-\text{NR}_{13}\text{R}_{14}$ wherein R_{13} is hydrogen and R_{14} is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.

20. (Amended) The compound or salt of Claim 61 wherein R^6 is $-\text{COR}^{10}$ wherein R^{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein:

R^{11} is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R^{12} is $-\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} together combine to form a heterocycle.

21. (Amended) The compound or salt of Claim 61 wherein R^6 is $-\text{COR}^{10}$ wherein R^{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein:

R^{11} is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R^{12} is $-NR^{13}R^{14}$ wherein R^{13} and R^{14} together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

22. (Amended) The compound or salt of Claim 61 wherein R^6 is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)-ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propylaminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one) -propylaminocarbonyl, or 3-(2-oxopyrrolidin-1-yl)propyl-aminocarbonyl.

32. (Amended) The compound or salt of Claim **[25]61** wherein:

R^1 is hydrogen;

R^2 is hydrogen, cyano, fluoro, chloro, or bromo;

R^3 is phenyl; and

R^4 is hydrogen.

33. (Amended) The compound or salt of Claim 61 wherein:

R^1 is hydrogen, unsubstituted lower alkyl, $-C(O)NR^8R^9$, unsubstituted cycloalkyl or aryl;

R^2 is hydrogen, halo, lower alkoxy, cyano, aryl or $-S(O)_2NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is hydrogen, aryl or alkyl;

R^3 is selected from the group consisting of hydrogen, lower alkoxy, $-C(O)R^{15}$, $-NR^{13}C(O)R^{14}$, aryl, and heteroaryl; and

R^4 is hydrogen.

43. (Amended) The compound of Claim 61 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein R^{12} is $-N^+(O^-)[N]R^{13}R^{14}$ [or $N(OH)R^{13}$] wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.

44. (Amended) The compound of Claim 61 wherein R^6 is **[2 (N hydroxy N ethylamino)ethylaminocarbonyl or] 2-[N⁺(O⁻)(C₂H₅)₂]ethyl-aminocarbonyl.**

46. (Amended) The compound or salt of **[any of the] Claim[s] [39, 40, 43, 44 or 20 22]61** wherein:

R⁵ is selected from the group consisting of hydrogen, or methyl; and

R⁷ is selected from the group consisting of methyl, hydrogen or phenyl.

47. (Amended) The compound or salt of Claim **[45]61** wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, chloro, fluoro, or bromo;

R³ is hydrogen; and

R⁴ is hydrogen.

48. (Amended) The compound or salt of Claim **[46]61** wherein:

R¹ is hydrogen;

R² is cyano, chloro, fluoro, or bromo;

R³ is hydrogen; and

R⁴ is hydrogen.

50. (Amended) A pharmaceutical composition, comprising a compound or salt of Claim **61** and, a pharmaceutically acceptable carrier or excipient.

51. (Amended) A pharmaceutical composition, comprising a compound or salt of Claim **[49]65** and, a pharmaceutically acceptable carrier or excipient.

52. (Amended) A method for the modulation of the catalytic activity of a protein kinase, comprising contacting said protein kinase with a compound or salt of Claim **61** or **[49]65**.